- Trials with a EudraCT protocol (1,138)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (53)
1,138 result(s) found for: Immunotherapy.
Displaying page 1 of 57.
EudraCT Number: 2012-004194-12 | Sponsor Protocol Number: CS-BM32-nasal-001 | Start Date*: 2012-10-23 |
Sponsor Name:Medizinische Universität Wien, HNO Klinik | ||
Full Title: The effect of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergy, on immunoglobulin levels in nasal secretions of patients suffering from seasonal allergic rhinitis | ||
Medical condition: Grass pollen allergy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002769-44 | Sponsor Protocol Number: ESAP | Start Date*: 2015-09-28 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: Efficacy and safety of an accelerated outpatient protocol for hymenoptera venom immunotherapy | |||||||||||||
Medical condition: Immunotherapy against systemic anaphylactic sting reactions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016815-39 | Sponsor Protocol Number: il-ASIT1 | Start Date*: 2010-01-15 |
Sponsor Name:Allergy Unit Department of Oto-rhino-Laryngology Lund/Malmö University Hospital | ||
Full Title: Is Intralymphatic Allergen Immunotherapy effective and safe: A human randomized clinical trial | ||
Medical condition: Seasonal Allergic rhinitis due to pollen from grass and betula verrucosa | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002944-18 | Sponsor Protocol Number: BIA-HDMP-201 | Start Date*: 2016-11-14 |
Sponsor Name:Bial Industrial Farmacéutica S.A. | ||
Full Title: MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC R... | ||
Medical condition: The disease under study is allergic rhinoconjunctivitis secondary to sensitization to DPT and DF. Included in the study are patients diagnosed with that disease who also have associated mild asthma... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023536-16 | Sponsor Protocol Number: ITN043AD | Start Date*: 2011-02-25 |
Sponsor Name:University of California, San Francisco, Immune Tolerance Network | ||
Full Title: A Randomised, Double-blind, Single-centre, Placebo controlled Study of Sublingual Immunotherapy and Subcutaneous Immunotherapy in Adults with Seasonal Allergic Rhinitis (ITN043AD) | ||
Medical condition: Grass-pollen induced rhinoconjunctivitis (hay fever). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003746-42 | Sponsor Protocol Number: om 145 | Start Date*: 2003-02-11 | |||||||||||
Sponsor Name:OSPEDALE ONCOLOGICO DI BARI | |||||||||||||
Full Title: Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma | |||||||||||||
Medical condition: metastatic kidney carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001459-22 | Sponsor Protocol Number: BIA-PAR-DEPOT | Start Date*: 2015-02-20 |
Sponsor Name:Bial Industrial Farmacéutica S.A. | ||
Full Title: OPEN CLINICAL TRIAL, MULTICENTER, WITH SUBCUTANEOUS IMMUNOTHERAPY IN DEPOT PRESENTATION, IN PATIENTS WITH ALLERGY RHINOCONJUNCTIVITIS SENSITIZED TO PARIETARIA JUDAICA | ||
Medical condition: PATIENTS WITH RHINOCONJUNCTIVITIS SENSITISED TO PARIETARIA JUDAICA | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000513-29 | Sponsor Protocol Number: CLU-2008-001 | Start Date*: 2008-09-30 |
Sponsor Name:ROXALL Medizin GmbH | ||
Full Title: Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dact... | ||
Medical condition: This clinical trial will evaluate the benefit of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® over placebo in patients with allergic rhinoconjunctivits. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002971-17 | Sponsor Protocol Number: FG-2018/05 | Start Date*: 2019-07-18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Centre Georges-François Leclerc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous r... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with the following solid malignancy: • Metastatic breast cancer • Metastatic prostate cancer • Metastatic lung cancer • Metastatic head and neck • Metastatic endometrial cancer • M... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003616-13 | Sponsor Protocol Number: TPX-0005-01 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:Turning Point Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ... | |||||||||||||
Medical condition: advanced solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005115-32 | Sponsor Protocol Number: 213824 | Start Date*: 2022-09-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Prog... | |||||||||||||
Medical condition: Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003266-13 | Sponsor Protocol Number: Com-IT-2 | Start Date*: 2021-09-14 |
Sponsor Name:Oslo University Hospital | ||
Full Title: A PHASE 2 RANDOMISED OPEN TWO-ARM STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF IMMUNOTHERAPY COMBINED WITH EXTENSIVE RADIATIOTHERAPY FOR THE TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER | ||
Medical condition: Non small cell lung cancer, stage IV Patients are eligible if when they are planned to start immunotherapy according to standard routines and are not in need of radiotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005768-74 | Sponsor Protocol Number: ImmunoSep | Start Date*: 2021-02-18 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: PERSONALIZED IMMUNOTHERAPY IN SEPSIS: A MULTICENTRE AND MULTINATIONAL, DOUBLE-BLIND, DOUBLE-DUMMY RANDOMIZED CLINICAL TRIAL (THE IMMUNOSEP TRIAL) | |||||||||||||
Medical condition: Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) NL (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004583-30 | Sponsor Protocol Number: BIA-DPT-P2-001 | Start Date*: 2012-01-16 |
Sponsor Name:BIAL Industrial Farmaceutica | ||
Full Title: A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCT... | ||
Medical condition: Allergic rhinoconjunctivitis with or without associated asthma. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000254-21 | Sponsor Protocol Number: MO39839 | Start Date*: 2021-04-20 | ||||||||||||||||
Sponsor Name:University Hospital Essen | ||||||||||||||||||
Full Title: Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) with or without tocilizumab (Actemra®) in local head and neck squamous cell carcinoma | ||||||||||||||||||
Medical condition: local squamous cell carcinoma of the head and neck | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006251-11 | Sponsor Protocol Number: HLS05/2011 | Start Date*: 2012-03-19 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Pilot clinical trial, controlled and randomized, Phase III, to evaluate security and efficacy of oral specific immunotherapy in HIV infected patients who suffer from grass pollen allergy. | |||||||||||||
Medical condition: HIV+ subjects with grass pollen allergy. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003809-26 | Sponsor Protocol Number: SP010 | Start Date*: 2013-12-04 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: Open-label, one-arm, multi-centre phase II clinical trial with second cycle of active cellular immunotherapy DCVAC/PCa in patients with localized prostate cancer after primary radical prostatectomy... | |||||||||||||
Medical condition: Localized prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003408-33 | Sponsor Protocol Number: ESR-21-21536 | Start Date*: 2023-04-25 | |||||||||||
Sponsor Name:TheraOp gGmbH | |||||||||||||
Full Title: PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC | |||||||||||||
Medical condition: Locally advanced, unresectable non-small-cell lung cancer (NSCLC) (Stage III) with a PD-L1-expression of ≥ 1% | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000594-24 | Sponsor Protocol Number: 12/014/TAR | Start Date*: 2012-04-19 | |||||||||||
Sponsor Name:Royal Sussex County Hospital | |||||||||||||
Full Title: An open study to investigate the effects of injection immunotherapy on allergen-specific T and B cell responses in adult patients with seasonal allergic rhinitis. | |||||||||||||
Medical condition: Allergic Rhinitis due to birch or grass pollen | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003832-96 | Sponsor Protocol Number: ChIm-NB-PL | Start Date*: 2021-10-13 | |||||||||||||||||||||
Sponsor Name:Jagiellonian University Medical College | |||||||||||||||||||||||
Full Title: Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to standard therapy and with relapsed or progressive disease | |||||||||||||||||||||||
Medical condition: Recurrent or progression of neuroblastoma or neuroblastoma refractory to first-line treatment | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
